HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo
暂无分享,去创建一个
T. Etrych | M. Studenovský | L. Kostka | B. Dvořáková | M. Kovář | L. Sivák | Jiřina Kovářová | Anna Rumlerová | Daniel Berdár
[1] T. Etrych,et al. HPMA-Based Polymer Conjugates for Repurposed Drug Mebendazole and Other Imidazole-Based Therapeutics , 2021, Polymers.
[2] V. Šubr,et al. Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[3] T. Etrych,et al. HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy , 2021, Pharmaceutics.
[4] T. Etrych,et al. Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma. , 2020, Acta biomaterialia.
[5] L. Rushworth,et al. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment , 2019, British Journal of Cancer.
[6] M. Jarvius,et al. Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition , 2019, BMC Research Notes.
[7] Hyun‐Kyung Kim,et al. Autophagy Is a Potential Target for Enhancing the Anti-Angiogenic Effect of Mebendazole in Endothelial Cells , 2019, Biomolecules & therapeutics.
[8] T. Mukhopadhyay,et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways , 2018, Scientific Reports.
[9] R. Burbano,et al. Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. , 2017, Toxicology in vitro : an international journal published in association with BIBRA.
[10] Claes R. Andersson,et al. The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation , 2017, Immunopharmacology and immunotoxicology.
[11] Emanuel F. Petricoin,et al. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma , 2017, Oncotarget.
[12] F. Liu,et al. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC) , 2017, Oncotarget.
[13] G. Riggins,et al. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model , 2016, Oncotarget.
[14] L. Domingo,et al. Analysis of mebendazole binding to its target biomolecule by laser flash photolysis. , 2016, Journal of photochemistry and photobiology. B, Biology.
[15] G. Riggins,et al. The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.
[16] F. Peng,et al. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells , 2015, Oncotarget.
[17] Y. Pommier,et al. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins , 2015, Proceedings of the National Academy of Sciences.
[18] J. Kopeček. Polymer-drug conjugates: origins, progress to date and future directions. , 2013, Advanced drug delivery reviews.
[19] K. Ulbrich,et al. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[20] Gary L Gallia,et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. , 2011, Neuro-oncology.
[21] Hiroshi Maeda,et al. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.
[22] Ruth Duncan,et al. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. , 2009, Advanced drug delivery reviews.
[23] T. Mrkvan,et al. In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy1 , 2009, The Journal of Immunology.
[24] S. Badar,et al. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. , 2009, Anticancer research.
[25] N. Doudican,et al. Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells , 2008, Molecular Cancer Research.
[26] J. M. Clancy,et al. Prodrugs for Amines , 2008, Molecules.
[27] Kazunori Kataoka,et al. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. , 2006, Pharmacology & therapeutics.
[28] K. Ulbrich,et al. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[29] Jack A Roth,et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. , 2002, Molecular cancer therapeutics.
[30] Jack A Roth,et al. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[32] M. Roberts,et al. The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. , 1985, British journal of clinical pharmacology.
[33] R. J. Allan,et al. The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. , 1982, British journal of clinical pharmacology.